Conferences
ASCO GU 2019: LATITUDE Study - Final Analysis of Phase III Study in Patients with Newly Diagnosed High-Risk Metastatic Castration-Naïve Prostate Cancer
February 15, 2019
ASCO GU 2019: Outcome of Men with Relapses after Adjuvant BEP for Clinical Stage I Nonseminoma
February 15, 2019
ASCO GU 2019: A Phase II, Open-label, Multi-arm Study of TAS-115 for Castration-resistant Prostate Cancer Patients with Bone Metastases
February 15, 2019
ASCO GU 2019: Long-term Outcomes of Hypoxia Modification in Bladder Preservation: Update from BCON Trial
February 15, 2019
ASCO GU 2019: A Randomized Trial Comparing Fluorocholine-PET/CT with Conventional Imaging in Prostate Cancer
February 15, 2019
ASCO GU 2019: Discussion on: The ARAMIS Trial, the Final Analysis of LATITUDE Study, and the ARCHES Trial
February 15, 2019
ASCO GU 2019: Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-Resistant Prostate Cancer
February 15, 2019
ASCO GU 2019: Skeletal Related Events in CTRIAL-IE 13-21: Radium-223 in Combination with Enzalutamide for Patients with mCRPC
February 15, 2019
ASCO GU 2019: Intensification Versus Deintensification in High-Risk Prostate Cancer
February 15, 2019
ASCO GU 2019: A Phase III Trial of Docetaxel versus Docetaxel and Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer: DORA
February 15, 2019
ASCO GU 2019: Cost-Effectiveness of Metastasis-Directed Therapy in the Setting of Oligometastatic Hormone-Sensitive Prostate Cancer
February 15, 2019
ASCO GU 2019: Quality of Life-Focused Decision-Making for Castrate-Sensitive Prostate Cancer
February 15, 2019
ARAMIS: Efficacy and Safety of Darolutamide in nmCRPC | ASCO GU 2019
February 15, 2019